Zahra Heydarifard

Dr. Zahra Heydarifard

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2023 in Journal of Medical Virology
Verified
Journal Article
Closed access
BMBita Mohammadi
Bita Mohammadi
Kamal DuaKamal Dua
Kamal Dua
MSMohammadreza Saghafi
Mohammadreza Saghafi
SSSACHIN Kumar SINGH
SACHIN Kumar SINGH
ZHZahra Heydarifard
Zahra Heydarifard
MZMilad Zandi
Milad Zandi

13 August 2024 in Journal of Innate Immunity
Verified
Journal Article
Open access
PDF file
RPReza Parnian
Reza Parnian
FHFatemeh Heydarifard
Fatemeh Heydarifard
FMFatemeh Sadat Mousavi
Fatemeh Sadat Mousavi
ZHZahra Heydarifard
Zahra Heydarifard
MZMilad Zandi
Milad Zandi
The re-emergence of the Mpox (formerly monkeypox) in 2022 in non-endemic countries has raised many concerns for global health due to its high transmissibility and mortality rate. A major challenge in fighting Mpox is its ability to evade the host's innate immune system, which is the first line of defense against viral infections. Mpox encodes various proteins that interfere with key antiviral pathways and mechanisms, such as the nuclear factor kappa B (NF-κB) signaling, cytokine production, complement and inflammasome activation, and chemokine binding. These proteins modulate the expression and function of innate immune mediators, such as interferons, interleukins, and toll-like receptors, and impair the recruitment and activation of innate immune cells, such as natural killer cells. By suppressing or altering these innate immune responses, Mpox enhances its replication and infection in the host tissues and organs, leading to systemic inflammation, tissue damage, and organ failure. This study reveals new insights into the molecular and cellular interactions between Mpox and the host’s innate immunity and identifies potential targets and strategies for antiviral interventions.

8 July 2023 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
MBMehdi Gholami Barzoki
Mehdi Gholami Barzoki
SMSomayeh Shatizadeh Malekshahi
Somayeh Shatizadeh Malekshahi
ZHZahra Heydarifard
Zahra Heydarifard
MMMohamad Javad Mahmodi
Mohamad Javad Mahmodi
HSHaleh Soltanghoraee
Haleh Soltanghoraee

27 December 2021 in Congenital Anomalies
Verified
Journal Article
Closed access
PDF file
ZHZahra Heydarifard
Zahra Heydarifard
SZSevrin Zadheidar
Sevrin Zadheidar
JYJila Yavarian
Jila Yavarian
SMSomayeh Shatizadeh Malekshahi
Somayeh Shatizadeh Malekshahi
SKShirin Kalantari
Shirin Kalantari
NSNazanin Zahra Shafiei-Jandaghi
Nazanin Zahra Shafiei-Jandaghi

29 September 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
ZNZahra Najafi-Olya
Zahra Najafi-Olya
ZHZahra Heydarifard
Zahra Heydarifard
MLMehdi Azizmohammad Looha
Mehdi Azizmohammad Looha
AAAkram Sadat Ahmadi
Akram Sadat Ahmadi
NYNeda Yarhamadi
Neda Yarhamadi
MSMoslem Safaei
Moslem Safaei
Background: The COVID-19 pandemic exacerbated antimicrobial resistance (AMR) in Iran, where up to 100% of hospitalized patients received antibiotics despite low bacterial co-infection rates. However, no comprehensive review has evaluated the burden of bacterial co-infections, antibiotic resistance (AR), and multi-drug resistance (MDR) across both hospitalized and non-hospitalized Iranian COVID-19 patients. This systematic review and meta-analysis aimed to determine the prevalence of bacterial infections, AR, and MDR during the COVID-19 era in Iran. Methods: Following PRISMA 2020 guidelines, we systematically searched MEDLINE (PubMed), Embase, Scopus, Web of Science, and Iranian regional databases for studies published from January 2020 to March 2025. The review protocol was registered with the Open Science Framework (OSF; https://doi.org/10.17605/OSF.IO/SCBRX ). Fifteen studies comprising 36,403 COVID-19 patients—33,989 inpatients (including 22,875 treated in intensive-care units) and 2,414 outpatients—met the inclusion criteria. We combined results from multiple studies to determine overall rates of bacterial infections, antibiotic resistance, and multi-drug resistance, using methods that account for differences between studies. Results: The pooled prevalence of bacterial co-infection among Iranian COVID-19 patients was 19.6% (95% CI: 17.8–21.4%) across hospitalized and non-hospitalized settings. Among hospitalized patients, secondary bacterial infections were predominantly caused by Gram-negative pathogens: Klebsiella pneumoniae (36.2%), Acinetobacter baumannii (28.4%), Escherichia coli (24.8%), and Pseudomonas aeruginosa (11.7%). High heterogeneity (I² >90%) was observed across most pooled estimates. Critical antimicrobial resistance rates were observed particularly in hospitalized settings, with carbapenem resistance reaching 91% for imipenem and 88% for meropenem in A. baumannii. Given that 63% of the cohort were ICU patients, the high secondary bacterial infection and resistance rates likely reflect risk factors such as mechanical ventilation and prolonged hospitalization. Conclusion: Iran’s AMR crisis during the COVID-19 era affects both hospitalized and non-hospitalized patients, with particularly concerning rates in healthcare settings. The predominance of hospitalized cases in available literature (ICU-heavy cohorts) reflects the urgent need for antimicrobial stewardship programs targeting hospital-based carbapenem-sparing regimens, while highlighting the need for improved surveillance across all COVID-19 care settings.

28 October 2021 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
ZHZahra Heydarifard
Zahra Heydarifard
MSMoslem Safaei
Moslem Safaei
SZSevrin Zadheidar
Sevrin Zadheidar
SESoroush Ehsan
Soroush Ehsan
NSNazanin Zahra Shafiei-Jandaghi
Nazanin Zahra Shafiei-Jandaghi
Patients with underlying health conditions are vulnerable to invasive fungal infection following COVID‐19. It seems that uncontrolled diabetes mellitus makes patients susceptible to both severe COVID‐19 and mucormycosis.